APA

Rassmann I., Thödtmann R., Mross M., Hüttmann A., Berdel W. E., Manegold C., Fiebig H. H., Kaeser-Fröhlich A., Burk K. & Hanauske A. R. (19990831). Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. : Investigational new drugs.

Chicago

Rassmann I, Thödtmann R, Mross M, Hüttmann A, Berdel W E, Manegold C, Fiebig H H, Kaeser-Fröhlich A, Burk K and Hanauske A R. 19990831. Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. : Investigational new drugs.

Harvard

Rassmann I., Thödtmann R., Mross M., Hüttmann A., Berdel W. E., Manegold C., Fiebig H. H., Kaeser-Fröhlich A., Burk K. and Hanauske A. R. (19990831). Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. : Investigational new drugs.

MLA

Rassmann I, Thödtmann R, Mross M, Hüttmann A, Berdel W E, Manegold C, Fiebig H H, Kaeser-Fröhlich A, Burk K and Hanauske A R. Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. : Investigational new drugs. 19990831.